Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Cerillion gives confident outlook, but shares drop after H1 results

(Sharecast News) - Shares in Cerillion said on Monday that it expects to hit market forecasts this year, but shares dropped sharply after the B2B software group reported a fall in interim profits. Adjusted EBITDA was down 9% year-on-year at £10m in the six months to 31 March, with revenues falling 7% to £20.9m and adjusted EBITDA margins slipping to 47.7% from 48.9%.

The company, which provides billing, charging and customer relationship management software, said the weaker top line was mainly a result of the weighing of expected licence renewals and extensions shifting into the second half, compared to last year when the bulk of theses occurred in the first half.

Nevertheless, there were bright spots in the first half, such as the signing of a major new five-year contract worth $11.4m in January with a major national telecoms operator in Armenia, and a £5.4m term renewal agreed in March with a major European customer.

Since the end of the first half, Cerillion also signed one of its largest deals to date. "This project is to facilitate the migration of an existing European customer's newly acquired customer base onto our product and platform. It further validates our offering as the customer chose to move its new customer base to Cerillion's SaaS-based platform instead of remaining with the incumbent tier-1 provider," said chief executive Louis Hall.

Cerillion said its back-order book was up 7% at £50.2m by the period-end, and up 23% as of the end of April to £56.2m.

"Based on new orders achieved to date and current trading, we believe Cerillion is well-placed to deliver market expectations for the full year and beyond. We continue to view long-term prospects with confidence," Hall said.

Despite the upbeat outlook,shares were down nearly 7% at 1,714.5p by 1008 BST, having gained more than 20% over the past month.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.